XOMA Royalty Corp - 8-K Filing
XOMA Royalty Corp completed its merger with Ligand Pharmaceuticals, delisted shares from Nasdaq, terminated a loan agreement, restructured as a holding company, and redeemed preferred stock. (Items: 1.02 Termination of a Material Definitive Agreement, 2.01 Completion of Acquisition or Disposition of Assets, 1.01 of the Company’s Current Report on Form 8-K filed with the SEC on April 27, 2026 is incorporated herein by reference, 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing)
Tickers: $XOMA